Top Story

High-intensity statin use low in patients with diabetes, high CVD risk

May 22, 2015

NASHVILLE, Tenn. - Patients with type 2 diabetes at very high risk for cardiovascular disease are often not taking high-intensity statins, further increasing their risk, and frequently modify their initial statin therapy, indicating intolerability or ineffectiveness of the drug, according to study findings presented here.

In a retrospective cohort study, researchers found that less than 23% of patients with type 2 diabetes at high risk for CVD initiated treatment with a high-intensity statin, whereas approximately 80% of patients who initiated statin therapy modified their index treatment.

Meeting News Coverage

Analysis: Most patients prescribed Qsymia as intended

May 22, 2015
NASHVILLE, Tenn. - Adults assigned the weight-loss drug Qsymia are mostly women and white, with a large percentage also taking medications for diabetes and hypertension…
In the Journals

Caffeine consumption reduces risk of erectile dysfunction

May 22, 2015
Men who consumed between 85 mg and 303 mg of caffeine per day were less likely to experience erectile dysfunction, compared with men who consumed less than 7 milligrams…
Priyathama Vellanki Meeting News Coverage

Clinical characteristics, hospital outcomes differ between type 1, type 2 diabetes

May 22, 2015
NASHVILLE, Tenn. - Age-matched patients with type 1 and type 2 diabetes reveal significant differences in inpatient clinical characteristics and hospital outcomes…
VIDEO: New osteoporosis guidelines for menopausal women to be released later this year Meeting News CoverageVideo

VIDEO: New osteoporosis guidelines for menopausal women to be released later this year

May 21, 2015
NASHVILLE, Tenn. — Pauline Camacho, MD, FACE, president elect of AACE, discusses the upcoming guidelines for postmenopausal women expected to be released later…
More News Headlines »
CME
Assessing Cornerstones for Successful Weight Loss

Assessing Cornerstones for Successful Weight Loss: Building a Foundation that Really Works

This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc.

Obesity has increased dramatically in the past 2 decades and is now considered a health care epidemic in the United…
More »
Meeting News Coverage Video
VIDEO: Year in Pituitary Disease examines new developments

VIDEO: Year in Pituitary Disease examines new developments

May 20, 2015
NASHVILLE, Tenn. — In this video exclusive, Mark Molitch, MD, discusses a number of new developments in…
More »
CME
Obesity Consults: Volume 2, Number 2 Obesity Forum 2014 Highlights

Obesity Consults: Volume 2, Number 2
Obesity Forum 2014 Highlights

This activity is supported by educational grants from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc; Eisai, Inc.; Novo Nordisk; Vivus, Inc.

Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. Treatment options…
More »
Current Issues
View the Current Issues
morganatic-roan